A large study found that expanded Medicaid coverage under the Affordable Care Act leads to better survival outcomes for young adults ages 18-39 newly diagnosed with cancer, particularly those who identified as Hispanic or non-Hispanic Black.
Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
